Reference - Detail
| RRC ID | 57812 |
|---|---|
| Author | Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X, Luo H, Wang H, Li Z, Jiang H. |
| Title | Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma. |
| Journal | J Immunol |
| Abstract |
Adoptive immunotherapy based on chimeric antigen receptor-modified T (CAR-T) cells has been demonstrated as one of the most promising therapeutic strategies in the treatment of malignancies. However, CAR-T cell therapy has shown limited efficacy for the treatment of solid tumors. This is, in part, because of tumor heterogeneity and a hostile tumor microenvironment, which could suppress adoptively transferred T cell activity. In this study, we, respectively, engineered human- or murine-derived-armored glypican-3 (GPC3)-specific CAR-T cells capable of inducibly expressing IL-12 (GPC3-28Z-NFAT-IL-12) T cells. The results showed that GPC3-28Z-NFAT-IL-12 T cells could lyse GPC3+ tumor cells specifically and increase cytokine secretion compared with GPC3-28Z T cells in vitro. In vivo, GPC3-28Z-NFAT-IL-12 T cells augmented the antitumor effect when encountering GPC3+ large tumor burdens, which could be attributed to IL-12 increasing IFN-γ production, favoring T cells infiltration and persistence. Furthermore, in immunocompetent hosts, low doses of GPC3-m28Z-mNFAT-mIL-12 T cells exerted superior antitumor efficacy without prior conditioning in comparison with GPC3-m28Z T cells. Also, mIL-12 secretion decreased regulatory T cell infiltration in established tumors. In conclusion, these findings demonstrated that the inducible expression of IL-12 could boost CAR-T function with less potential side effects, both in immunodeficient and immunocompetent hosts. The inducibly expressed IL-12-armored GPC3-CAR-T cells could broaden the application of CAR-T-based immunotherapy to patients intolerant of lymphodepletion chemotherapy and might provide an alternative therapeutic strategy for patients with GPC3+ cancers. |
| Volume | 203(1) |
| Pages | 198-207 |
| Published | 2019-7-1 |
| DOI | 10.4049/jimmunol.1800033 |
| PII | jimmunol.1800033 |
| PMID | 31142602 |
| MeSH | Animals Carcinoma, Hepatocellular / immunology Carcinoma, Hepatocellular / therapy* Glypicans / genetics Glypicans / immunology Glypicans / metabolism* HEK293 Cells Humans Immunotherapy, Adoptive / methods* Interleukin-12 / genetics Interleukin-12 / immunology Interleukin-12 / metabolism* Liver Neoplasms / immunology Liver Neoplasms / therapy* Lymphocytes, Tumor-Infiltrating / physiology* Lymphocytes, Tumor-Infiltrating / transplantation Mice Mice, Inbred C57BL Protein Engineering Receptors, Antigen, T-Cell, alpha-beta / genetics T-Cell Antigen Receptor Specificity / genetics Tumor Microenvironment Xenograft Model Antitumor Assays |
| IF | 4.718 |
| Times Cited | 12 |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | Patent(IFI CLAIMS) |
| Total number of mentions | 20 |
| Altmetric score changes over past 6months | 3.0 |
| Resource | |
| Human and Animal Cells | HuH-7 |